LON:HVO

hVIVO Interim Earnings Results & Report

hVIVO logo
GBX 4.62 -0.13 (-2.74%)
As of 12:33 PM Eastern

hVIVO reported Interim earnings on September 23, 2025. The company reported EPS of -GBX 0.29.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

hVIVO EPS Results

Actual EPS
-GBX 0.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

hVIVO Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

hVIVO Interim Earnings FAQ

hVIVO (LON:HVO) reported earnings of -GBX 0.29 per share for Interim. The report was announced on Tuesday, September 23, 2025.

hVIVO Earnings Headlines

hVIVO names new finance chief to support growth strategy
Appointment of Chief Financial Officer
Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
hVIVO appoints Caroline Shaw to board as Sullivan steps down
See More hVIVO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like hVIVO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on hVIVO and other key companies, straight to your email.

About hVIVO

hVIVO (LON:HVO) (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

View hVIVO Profile